Trial Profile
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary)
- Indications Cancer; Lymphoma; Malignant melanoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 27 Jan 2024 Results (n=15; data cutoff date: as of 01 Nov 2022) reporting safety and clinical activity data from cohort 3 and 4 presented at the 2024 Genitourinary Cancers Symposium
- 29 Nov 2023 Planned End Date changed from 27 Jan 2025 to 14 Dec 2024.
- 29 Nov 2023 Planned primary completion date changed from 27 Jan 2025 to 14 Dec 2024.